c-CPE 194 also augmented the cytotoxicity of gemcitabine and S-1 (two anticancer drugs), reduced the expression of Claudin-4, and improved MAPK activity in a poorly differentiated pancreatic cancer cell line, PANC-1. Here, CLDN4 is linked to pancreatic neoplasm.